338 related articles for article (PubMed ID: 9673796)
21. Opioid activity of dermenkephalin analogues in the guinea-pig myenteric plexus and the hamster vas deferens.
Sagan S; Corbett AD; Amiche M; Delfour A; Nicolas P; Kosterlitz HW
Br J Pharmacol; 1991 Oct; 104(2):428-32. PubMed ID: 1665735
[TBL] [Abstract][Full Text] [Related]
22. Radioligand-dependent discrepancy in agonist affinities enhanced by mutations in the kappa-opioid receptor.
Hjorth SA; Thirstrup K; Schwartz TW
Mol Pharmacol; 1996 Oct; 50(4):977-84. PubMed ID: 8863844
[TBL] [Abstract][Full Text] [Related]
23. Comparison of dynorphin-selective Kappa receptors in mouse vas deferens and guinea pig ileum. Spare receptor fraction as a determinant of potency.
Cox BM; Chavkin C
Mol Pharmacol; 1983 Jan; 23(1):36-43. PubMed ID: 6135144
[No Abstract] [Full Text] [Related]
24. Mu- and delta-opioid receptors inhibitorily linked to dopamine-sensitive adenylate cyclase in rat striatum display a selectivity profile toward endogenous opioid peptides different from that of presynaptic mu, delta and kappa receptors.
Schoffelmeer AN; De Vries TJ; Hogenboom F; Mulder AH
J Pharmacol Exp Ther; 1993 Oct; 267(1):205-10. PubMed ID: 8229747
[TBL] [Abstract][Full Text] [Related]
25. [2',6'-Dimethyltyrosine]dynorphin A(1-11)-NH2 analogues lacking an N-terminal amino group: potent and selective kappa opioid antagonists.
Lu Y; Nguyen TM; Weltrowska G; Berezowska I; Lemieux C; Chung NN; Schiller PW
J Med Chem; 2001 Sep; 44(19):3048-53. PubMed ID: 11543672
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and opioid activity of side-chain-to-side-chain cyclic dynorphin A-(1-11) amide analogues cyclized between positions 2 and 5. 1. Substitutions in position 3.
Vig BS; Murray TF; Aldrich JV
J Med Chem; 2004 Jan; 47(2):446-55. PubMed ID: 14711314
[TBL] [Abstract][Full Text] [Related]
27. Benzomorphan sites are ligand recognition sites of putative epsilon-receptors.
Chang KJ; Blanchard SG; Cuatrecasas P
Mol Pharmacol; 1984 Nov; 26(3):484-8. PubMed ID: 6149459
[TBL] [Abstract][Full Text] [Related]
28. Dynorphin A analogs containing a conformationally constrained phenylalanine derivative in position 4: reversal of preferred stereochemistry for opioid receptor affinity and discrimination of kappa vs. delta receptors.
Aldrich JV; Zheng QI; Murray TF
Chirality; 2001; 13(3):125-9. PubMed ID: 11270320
[TBL] [Abstract][Full Text] [Related]
29. Activity profiles of dalargin and its analogues in mu-, delta- and kappa-opioid receptor selective bioassays.
Pencheva N; Pospisek J; Hauzerova L; Barth T; Milanov P
Br J Pharmacol; 1999 Oct; 128(3):569-76. PubMed ID: 10516634
[TBL] [Abstract][Full Text] [Related]
30. Design and synthesis of 1-aminocycloalkane-1-carboxylic acid-substituted deltorphin analogues: unique delta and mu opioid activity in modified peptides.
Breveglieri A; Guerrini R; Salvadori S; Bianchi C; Bryant SD; Attila M; Lazarus LH
J Med Chem; 1996 Feb; 39(3):773-80. PubMed ID: 8576920
[TBL] [Abstract][Full Text] [Related]
31. Selectivities of opioid peptide analogues as agonists and antagonists at the delta-receptor.
Corbett AD; Gillan MG; Kosterlitz HW; McKnight AT; Paterson SJ; Robson LE
Br J Pharmacol; 1984 Sep; 83(1):271-9. PubMed ID: 6091824
[TBL] [Abstract][Full Text] [Related]
32. 125I-DPDYN, monoiodo [D-Pro10]- dynorphin (1-11), is an effective and useful tool for the study of kappa opioid receptors.
Gairin JE; Jomary C; Cros J; Meunier JC
NIDA Res Monogr; 1986; 75():232-5. PubMed ID: 2893266
[TBL] [Abstract][Full Text] [Related]
33. N,N-diallyl-tyrosyl substitution confers antagonist properties on the kappa-selective opioid peptide [D-Pro10]dynorphin A(1-11).
Gairin JE; Mazarguil H; Alvinerie P; Botanch C; Cros J; Meunier JC
Br J Pharmacol; 1988 Dec; 95(4):1023-30. PubMed ID: 2905908
[TBL] [Abstract][Full Text] [Related]
34. Synthesis, biological evaluation, and quantitative receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as novel tifluadom-like ligands with high affinity and selectivity for kappa-opioid receptors.
Cappelli A; Anzini M; Vomero S; Menziani MC; De Benedetti PG; Sbacchi M; Clarke GD; Mennuni L
J Med Chem; 1996 Feb; 39(4):860-72. PubMed ID: 8632410
[TBL] [Abstract][Full Text] [Related]
35. Effects of modifications of residues in position 3 of dynorphin A(1-11)-NH2 on kappa receptor selectivity and potency.
Lung FD; Meyer JP; Lou BS; Xiang L; Li G; Davis P; DeLeon IA; Yamamura HI; Porreca F; Hruby VJ
J Med Chem; 1996 Jun; 39(13):2456-60. PubMed ID: 8691442
[TBL] [Abstract][Full Text] [Related]
36. Dynorphin A as a potential endogenous ligand for four members of the opioid receptor gene family.
Zhang S; Tong Y; Tian M; Dehaven RN; Cortesburgos L; Mansson E; Simonin F; Kieffer B; Yu L
J Pharmacol Exp Ther; 1998 Jul; 286(1):136-41. PubMed ID: 9655852
[TBL] [Abstract][Full Text] [Related]
37. Dynorphin inhibition of the neurotensin contractile activity on the myenteric plexus.
Huidobro-Toro JP; Zhu YX; Lee NM; Loh HH; Way EL
J Pharmacol Exp Ther; 1984 Feb; 228(2):293-303. PubMed ID: 6141281
[TBL] [Abstract][Full Text] [Related]
38. De novo design, synthesis, and biological activities of high-affinity and selective non-peptide agonists of the delta-opioid receptor.
Liao S; Alfaro-Lopez J; Shenderovich MD; Hosohata K; Lin J; Li X; Stropova D; Davis P; Jernigan KA; Porreca F; Yamamura HI; Hruby VJ
J Med Chem; 1998 Nov; 41(24):4767-76. PubMed ID: 9822547
[TBL] [Abstract][Full Text] [Related]
39. Opioid receptor selectivity of dynorphin gene products.
James IF; Fischli W; Goldstein A
J Pharmacol Exp Ther; 1984 Jan; 228(1):88-93. PubMed ID: 6141278
[TBL] [Abstract][Full Text] [Related]
40. The pharmacological profile of BAM 18.
Hurlbut DE; Evans CJ; Barchas JD; Leslie FM
NIDA Res Monogr; 1986; 75():81-4. PubMed ID: 2829012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
